Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroid...
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
Data to be presented in oral session at ASGCT 2024 Paris, France, April – Coave Therapeutics (‘Coave'), a genetic medicine company focused on developing life-changing therapies, announces today that preclinical studies on its novel Conjugated AAV (coAAV) gene therapy vectors demonstrate promising results for ocular gene therapy. Engineered coAAV vectors, generated using Coave's ALIGATER™ platform, show the ability to increase both the distribution and expression patterns of transgenes delivered via suprachoroidal administration, effectively improving the targeting of key tissues at the back of the eye. This advancement suggests a new, potentially impactful approach for treating acquired retinal diseases. These data, generated in collaboration with REGENXBIO, will be presented at the 2024 American Society of Gene & Cell Therapy (ASGCT) meeting, which will be held virtually and in person in Baltimore, MD, US May 7-11. Oral presentation details are as follows: Abstract Title Ident
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencesPR Newswire
- REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
RGNX
Earnings
- 5/8/24 - Miss
RGNX
Sec Filings
- 5/16/24 - Form 4
- 5/14/24 - Form 144
- 5/8/24 - Form 10-Q
- RGNX's page on the SEC website